Investigational drug · Phase 2
B1962
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "B1962"
First trial start
2024
Dec 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "B1962", any sponsor or status.
Conditions studied
As listed on its trial records.
- Recurrent Platinum-resistant Epithelial Ovarian Cancer
- Triple Negative Breast Cancer (TNBC)
- Cervical Cancers
- Small Cell Lung Cancer
- Hepatocellular Carcinoma (HCC)
- Colorectal Cancer
- Non-Squamous Non-Small Cell Lung Cancer
- Advanced Colorectal Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Ovarian cancer · Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "B1962" as an intervention, largest first.
- A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsNot yet recruiting
Tasly Biopharmaceuticals Co., Ltd.Industry
NCT06724263 · 120 participants (planned) · Start Dec 2024 · Primary completion Aug 2026
Drug: B1962 · For: Recurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervical Cancers and 4 more
Sites: Shanghai, China
- A Multicenter, Open Phase IIb Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Colorectal CancerNot yet recruiting
Tasly Biopharmaceuticals Co., Ltd.Industry
NCT06838546 · 80 participants (planned) · Start Feb 24, 2025 · Primary completion Jan 1, 2027
Drug: B1962 · For: Advanced Colorectal Cancer
Sites: Hanzhou, China
- A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid TumorsStatus unknown
Tasly Biopharmaceuticals Co., Ltd.Industry
NCT05650385 · 68 participants (planned) · Start Dec 2022 · Primary completion Dec 2023
Drug: B1962 · For: Neoplasms Malignant
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.